Characteristics of bisphosphonate-related osteonecrosis of the jaw after kidney transplantation

Wonse Park, Soo Hyung Lee, Kyung Ran Park, Seung Hee Rho, Won Yoon Chung, Hyung Jun Kim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Renal transplantation is the definitive treatment of chronic renal failure, and osteoporosis in patients after renal transplantation is caused by the use of high-dose corticosteroids, reduced renal function, and the use of immunosuppressant. While bisphosphonates inhibit osteoclastic activities, they are the drug of choice for the treatment and prevention of osteoporosis. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) becomes a problematic issue. There are few reports on BRONJ in patients after renal transplantation, so many oral bisphosphonates commonly prescribed in patients after renal transplantation to prevent osteoporosis have no warning of BRONJ. We analyzed the records of patients with BRONJ from January 2009 to December 2010. Among the patients with BRONJ, we selected patients who underwent transplantation of the kidney. Demographic data, drug-related factors, and clinical characteristics were evaluated using chart review. A total of 128 patients were categorized as having BRONJ, and there were 3 patients with a history of kidney transplantation. The average age was 54.6 years, and 2 victims were men. All patients received oral bisphosphonates for more than 2 years (range, 2-7 y; average, 58.6 mo). All patients had hypertension, diabetes mellitus, history of high-dose corticosteroids, and taking immunosuppressant drugs. Bisphosphonate-related osteonecrosis of the jaw occurred in the maxilla in all patients, which is classified as stage 3 because of the involved sinus. Extraction was the main provoking factor in all patients. In conclusion, even at a relatively young age, BRONJ in the maxilla can be developed by intake of oral bisphosphonate after kidney transplantation. Dental care for patients before and after undergoing renal transplantation should be emphasized to reduce the risk of BRONJ.

Original languageEnglish
JournalJournal of Craniofacial Surgery
Volume23
Issue number5
DOIs
Publication statusPublished - 2012 Sep 1

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Kidney Transplantation
Diphosphonates
Osteoporosis
Maxilla
Immunosuppressive Agents
Adrenal Cortex Hormones
Pharmaceutical Preparations
Dental Care

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Surgery

Cite this

Park, Wonse ; Lee, Soo Hyung ; Park, Kyung Ran ; Rho, Seung Hee ; Chung, Won Yoon ; Kim, Hyung Jun. / Characteristics of bisphosphonate-related osteonecrosis of the jaw after kidney transplantation. In: Journal of Craniofacial Surgery. 2012 ; Vol. 23, No. 5.
@article{003a8c5447a84532af2c47716de3d7ba,
title = "Characteristics of bisphosphonate-related osteonecrosis of the jaw after kidney transplantation",
abstract = "Renal transplantation is the definitive treatment of chronic renal failure, and osteoporosis in patients after renal transplantation is caused by the use of high-dose corticosteroids, reduced renal function, and the use of immunosuppressant. While bisphosphonates inhibit osteoclastic activities, they are the drug of choice for the treatment and prevention of osteoporosis. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) becomes a problematic issue. There are few reports on BRONJ in patients after renal transplantation, so many oral bisphosphonates commonly prescribed in patients after renal transplantation to prevent osteoporosis have no warning of BRONJ. We analyzed the records of patients with BRONJ from January 2009 to December 2010. Among the patients with BRONJ, we selected patients who underwent transplantation of the kidney. Demographic data, drug-related factors, and clinical characteristics were evaluated using chart review. A total of 128 patients were categorized as having BRONJ, and there were 3 patients with a history of kidney transplantation. The average age was 54.6 years, and 2 victims were men. All patients received oral bisphosphonates for more than 2 years (range, 2-7 y; average, 58.6 mo). All patients had hypertension, diabetes mellitus, history of high-dose corticosteroids, and taking immunosuppressant drugs. Bisphosphonate-related osteonecrosis of the jaw occurred in the maxilla in all patients, which is classified as stage 3 because of the involved sinus. Extraction was the main provoking factor in all patients. In conclusion, even at a relatively young age, BRONJ in the maxilla can be developed by intake of oral bisphosphonate after kidney transplantation. Dental care for patients before and after undergoing renal transplantation should be emphasized to reduce the risk of BRONJ.",
author = "Wonse Park and Lee, {Soo Hyung} and Park, {Kyung Ran} and Rho, {Seung Hee} and Chung, {Won Yoon} and Kim, {Hyung Jun}",
year = "2012",
month = "9",
day = "1",
doi = "10.1097/SCS.0b013e31825b33f6",
language = "English",
volume = "23",
journal = "Journal of Craniofacial Surgery",
issn = "1049-2275",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Characteristics of bisphosphonate-related osteonecrosis of the jaw after kidney transplantation. / Park, Wonse; Lee, Soo Hyung; Park, Kyung Ran; Rho, Seung Hee; Chung, Won Yoon; Kim, Hyung Jun.

In: Journal of Craniofacial Surgery, Vol. 23, No. 5, 01.09.2012.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Characteristics of bisphosphonate-related osteonecrosis of the jaw after kidney transplantation

AU - Park, Wonse

AU - Lee, Soo Hyung

AU - Park, Kyung Ran

AU - Rho, Seung Hee

AU - Chung, Won Yoon

AU - Kim, Hyung Jun

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Renal transplantation is the definitive treatment of chronic renal failure, and osteoporosis in patients after renal transplantation is caused by the use of high-dose corticosteroids, reduced renal function, and the use of immunosuppressant. While bisphosphonates inhibit osteoclastic activities, they are the drug of choice for the treatment and prevention of osteoporosis. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) becomes a problematic issue. There are few reports on BRONJ in patients after renal transplantation, so many oral bisphosphonates commonly prescribed in patients after renal transplantation to prevent osteoporosis have no warning of BRONJ. We analyzed the records of patients with BRONJ from January 2009 to December 2010. Among the patients with BRONJ, we selected patients who underwent transplantation of the kidney. Demographic data, drug-related factors, and clinical characteristics were evaluated using chart review. A total of 128 patients were categorized as having BRONJ, and there were 3 patients with a history of kidney transplantation. The average age was 54.6 years, and 2 victims were men. All patients received oral bisphosphonates for more than 2 years (range, 2-7 y; average, 58.6 mo). All patients had hypertension, diabetes mellitus, history of high-dose corticosteroids, and taking immunosuppressant drugs. Bisphosphonate-related osteonecrosis of the jaw occurred in the maxilla in all patients, which is classified as stage 3 because of the involved sinus. Extraction was the main provoking factor in all patients. In conclusion, even at a relatively young age, BRONJ in the maxilla can be developed by intake of oral bisphosphonate after kidney transplantation. Dental care for patients before and after undergoing renal transplantation should be emphasized to reduce the risk of BRONJ.

AB - Renal transplantation is the definitive treatment of chronic renal failure, and osteoporosis in patients after renal transplantation is caused by the use of high-dose corticosteroids, reduced renal function, and the use of immunosuppressant. While bisphosphonates inhibit osteoclastic activities, they are the drug of choice for the treatment and prevention of osteoporosis. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) becomes a problematic issue. There are few reports on BRONJ in patients after renal transplantation, so many oral bisphosphonates commonly prescribed in patients after renal transplantation to prevent osteoporosis have no warning of BRONJ. We analyzed the records of patients with BRONJ from January 2009 to December 2010. Among the patients with BRONJ, we selected patients who underwent transplantation of the kidney. Demographic data, drug-related factors, and clinical characteristics were evaluated using chart review. A total of 128 patients were categorized as having BRONJ, and there were 3 patients with a history of kidney transplantation. The average age was 54.6 years, and 2 victims were men. All patients received oral bisphosphonates for more than 2 years (range, 2-7 y; average, 58.6 mo). All patients had hypertension, diabetes mellitus, history of high-dose corticosteroids, and taking immunosuppressant drugs. Bisphosphonate-related osteonecrosis of the jaw occurred in the maxilla in all patients, which is classified as stage 3 because of the involved sinus. Extraction was the main provoking factor in all patients. In conclusion, even at a relatively young age, BRONJ in the maxilla can be developed by intake of oral bisphosphonate after kidney transplantation. Dental care for patients before and after undergoing renal transplantation should be emphasized to reduce the risk of BRONJ.

UR - http://www.scopus.com/inward/record.url?scp=84867813654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867813654&partnerID=8YFLogxK

U2 - 10.1097/SCS.0b013e31825b33f6

DO - 10.1097/SCS.0b013e31825b33f6

M3 - Article

VL - 23

JO - Journal of Craniofacial Surgery

JF - Journal of Craniofacial Surgery

SN - 1049-2275

IS - 5

ER -